Aegis Therapeutics LLC (Aegis) announced today that they have signed a License Agreement providing Roche access to Aegis' proprietary ProTek® stabilization technology. The ProTek® technology covers the use of specific excipients as stabilizers in certain manufacturing processes and formulations of protein-based therapeutics.
Under the terms of the agreement, Aegis will receive undisclosed up-front licensing fees and individual product-related event and royalty payments.
Edward T. Maggio, PhD, Chief Executive Officer of Aegis, said, "We are pleased to be working with Roche, an innovative world leader in monoclonal antibody and peptide based therapeutics. We view this agreement as a significant validation of our proprietary ProTek® peptide and protein stabilization technology."
Vaccines targeting chronic diseases show promise in combatting age-related conditions